<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311430513</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311430513</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>View point</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The last word on the so-called ‘Rowell’s syndrome’?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Antiga</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311430513">1</xref>
<xref ref-type="aff" rid="aff1-0961203311430513">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203311430513"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Caproni</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311430513">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonciani</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311430513">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bonciolini</surname><given-names>V</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311430513">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fabbri</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311430513">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203311430513"><sup>1</sup>Department of Medical and Surgical Critical Care, Section of Clinical, Allergo-immunological and Infettivological Dermatology, University of Florence, Florence, Italy; and <sup>2</sup>Department of Clinical Physiopathology, University of Florence, Florence, Italy</aff>
<author-notes>
<corresp id="corresp1-0961203311430513">Emiliano Antiga, MD, Department of Medical and Surgical Critical Care, Section of Clinical, Allergo-immunological and Infettivological Dermatology, University of Florence, Piazza Indipendenza, 11, 50129 Florence, Italy Email: <email>emiliano.antiga@unifi.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>6</issue>
<fpage>577</fpage>
<lpage>585</lpage>
<history>
<date date-type="received"><day>23</day><month>6</month><year>2011</year></date>
<date date-type="accepted"><day>27</day><month>10</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>To date, 71 patients having the so-called ‘Rowell’s syndrome’ (RS) have been reported in the literature. However, most of them did not show all the clinical and serological features first described by Rowell and co-workers in 1963. Moreover, since then, subacute cutaneous lupus erythematosus (SCLE) has been identified and the diagnostic criteria as well as the clinical features of erythema multiforme (EM) defined. Accordingly several authors have questioned the existence of RS over the past years. In the present paper, the main clinical, histopathological and immunopathological features of both SCLE and EM are described and all of the cases of RS reported in the literature are also reviewed in depth. A real association between discoid LE and EM was present only in a minority of cases and could be considered a mere coincidence. As for other associations, e.g. those between CLE and lichen planus or psoriasis, the coexistence of CLE and EM does not justify the framing of a separate syndrome as suggested by Rowell et al.</p>
</abstract>
<kwd-group>
<kwd>discoid lupus erythematosus</kwd>
<kwd>erythema multiforme</kwd>
<kwd>Rowell’s syndrome</kwd>
<kwd>subacute cutaneous lupus erythematosus</kwd>
<kwd>systemic lupus erythematosus</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311430513" sec-type="intro"><title>Introduction</title>
<p>In 1963, Rowell, Beck and Anderson<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup> described four female patients presenting with the clinical picture of chronic discoid lupus erythematosus (DLE) associated with annular lesions, clinically and histologically resembling erythema multiforme (EM). All patients also showed erythrocyanosis of the legs and chilblains.</p>
<p>These patients had typical immunological findings, consisting of the speckled type of antinuclear antibodies (ANAs), the anti-SjT type of precipitating antibodies to saline extract of human tissue and positive rheumatoid factor (RF). Later, it turned out that anti-SjT antibodies are identical to those of anti-La/SSB and anti-Ro/SSA.<sup><xref ref-type="bibr" rid="bibr2-0961203311430513">2</xref></sup> Rowell et al. stated that this association of a distinctive clinical picture with specific immunological alterations was sufficiently characteristic to justify regarding it as a new syndrome.</p>
<p>Since 1963, 71 patients having the so-called Rowell’s syndrome (RS) have been reported in the literature. However, most of them did not show all the clinical and serological features firstly described by Rowell and co-workers. Since then, a new specific type of cutaneous LE (CLE), namely subacute CLE (SCLE), was identified,<sup><xref ref-type="bibr" rid="bibr3-0961203311430513">3</xref>,<xref ref-type="bibr" rid="bibr4-0961203311430513">4</xref></sup> and the diagnostic criteria as well as the clinical features of EM defined.<sup><xref ref-type="bibr" rid="bibr5-0961203311430513">5</xref></sup> Accordingly, several authors have questioned the existence of RS over the past years.<sup><xref ref-type="bibr" rid="bibr6-0961203311430513">6</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr8-0961203311430513">8</xref></sup></p>
<p>In the present paper, the main clinical, histopathological and immunopathological features of both SCLE and EM are described. We also review in depth all the cases of RS reported in the literature, in order to answer the question of whether RS should be regarded as a distinct clinical entity or simply as an incidental association between LE and EM.</p></sec>
<sec id="sec2-0961203311430513"><title>Subacute cutaneous lupus erythematosus: clinical and immunopathological findings</title>
<p>In 1977, Gilliam reported a particular subset of CLE, with specific clinical and serological features, occurring preferentially in white females, and called it SCLE.<sup><xref ref-type="bibr" rid="bibr3-0961203311430513">3</xref></sup> SCLE was then better defined by Sontheimer et al. in 1979;<sup><xref ref-type="bibr" rid="bibr9-0961203311430513">9</xref></sup> it shows a significant coincidence with HLA-DR2, -DR3, -DQ2 and DRw52,<sup><xref ref-type="bibr" rid="bibr10-0961203311430513">10</xref></sup> and occurs in 7–27% of patients with LE, mostly Caucasian females of all ages.<sup><xref ref-type="bibr" rid="bibr4-0961203311430513">4</xref>,<xref ref-type="bibr" rid="bibr9-0961203311430513">9</xref></sup></p>
<p>Certain drugs, especially hydrochlorothiazide, angiotensin-converting enzyme inhibitors, and calcium channel blockers, have been associated with the onset and/or exacerbation of this disease.<sup><xref ref-type="bibr" rid="bibr11-0961203311430513">11</xref>,<xref ref-type="bibr" rid="bibr12-0961203311430513">12</xref></sup> In recent years, terbinafine has also been reported to induce SCLE.<sup><xref ref-type="bibr" rid="bibr13-0961203311430513">13</xref></sup> Patients with SCLE typically have prominent cutaneous and musculoskeletal complaints, do not generally develop a severe systemic disease, and only half of them have four or more American College of Rheumatology (ACR) criteria for the diagnosis of systemic LE (SLE).<sup><xref ref-type="bibr" rid="bibr14-0961203311430513">14</xref>,<xref ref-type="bibr" rid="bibr15-0961203311430513">15</xref></sup></p>
<p>Initially, SCLE lesions present with erythematous papules that evolve into scaly papulosquamous or annular/polycyclic plaques.<sup><xref ref-type="bibr" rid="bibr9-0961203311430513">9</xref></sup> A recent study of our group found that 42% of the patients with SCLE studied show the annular/polycyclic form, 39% papulosquamous form, and 16% both manifestations.<sup><xref ref-type="bibr" rid="bibr16-0961203311430513">16</xref></sup> Generally, lesions of this subtype heal without scarring but can leave long-lasting and permanent hypochromic changes, both representing a ‘clue’ for the clinical diagnosis.<sup><xref ref-type="bibr" rid="bibr17-0961203311430513">17</xref></sup></p>
<p>SCLE shows a characteristic distribution of lesions on sun-exposed areas, in particular the upper chest and back, deltoids, extensor surface of the arms, and less often face and scalp.<sup><xref ref-type="bibr" rid="bibr16-0961203311430513">16</xref>,<xref ref-type="bibr" rid="bibr17-0961203311430513">17</xref></sup> Interestingly, 27–100% of patients with SCLE have been reported to be abnormally photosensitive. Phototest results were shown to be positive in 63% of instances after UVA or UVB irradiation. Exposure to UV can precipitate or worsen SCLE lesions.<sup><xref ref-type="bibr" rid="bibr18-0961203311430513">18</xref></sup> Photosensitizing medications were demonstrated to trigger photo-induced reactions in SCLE patients.<sup><xref ref-type="bibr" rid="bibr19-0961203311430513">19</xref></sup></p>
<p>Several other skin lesions that are not specific for LE have been described in patients with SCLE, including painless mucous membrane erosions.<sup><xref ref-type="bibr" rid="bibr20-0961203311430513">20</xref></sup></p>
<p>Patients with SCLE may develop localized facial acute CLE, which has been seen in 7–100% of patients.<sup><xref ref-type="bibr" rid="bibr21-0961203311430513">21</xref>,<xref ref-type="bibr" rid="bibr22-0961203311430513">22</xref></sup> Several reports have also highlighted that up to 29% of patients with SCLE develop DLE lesions during their clinical course<sup><xref ref-type="bibr" rid="bibr20-0961203311430513">20</xref>,<xref ref-type="bibr" rid="bibr21-0961203311430513">21</xref>,<xref ref-type="bibr" rid="bibr23-0961203311430513">23</xref></sup> and, interestingly, 19% of the original cohort of patients with SCLE had classical DLE.<sup><xref ref-type="bibr" rid="bibr9-0961203311430513">9</xref></sup></p>
<p>In 60–80% of SCLE patients, ANAs are detected when human tissue is used as a substrate.<sup><xref ref-type="bibr" rid="bibr23-0961203311430513">23</xref>,<xref ref-type="bibr" rid="bibr24-0961203311430513">24</xref></sup> With immunodiffusion techniques, anti-Ro/SSA antibodies have been detected in 40–100% of patients with SCLE,<sup><xref ref-type="bibr" rid="bibr25-0961203311430513">25</xref></sup> while anti-La/SSBs have been observed in 12–42%.<sup><xref ref-type="bibr" rid="bibr26-0961203311430513">26</xref></sup> The Ro/SSA antibodies are directed against ribonucleoproteins consisting of a 60 kD peptide and an antigenically distinct 52 kD polypeptide.<sup><xref ref-type="bibr" rid="bibr27-0961203311430513">27</xref>,<xref ref-type="bibr" rid="bibr28-0961203311430513">28</xref></sup> Anti-dsDNA antibodies have been reported in 1.2–10% of SCLE patients.<sup><xref ref-type="bibr" rid="bibr20-0961203311430513">20</xref>,<xref ref-type="bibr" rid="bibr29-0961203311430513">29</xref></sup> RF is present in approximately one-third of the patients.<sup><xref ref-type="bibr" rid="bibr20-0961203311430513">20</xref>,<xref ref-type="bibr" rid="bibr24-0961203311430513">24</xref></sup></p>
<p>Several unusual clinical subtypes of SCLE have been reported. Massone et al. reported a case of SCLE with EM-like cutaneous lesions.<sup><xref ref-type="bibr" rid="bibr30-0961203311430513">30</xref></sup> Lyon et al. reported two cases of delayed diagnosis of SCLE because of the clinical and histopathological similarities between SCLE and EM.<sup><xref ref-type="bibr" rid="bibr31-0961203311430513">31</xref></sup> Grant,<sup><xref ref-type="bibr" rid="bibr32-0961203311430513">32</xref></sup> and Wechsler and Stourides<sup><xref ref-type="bibr" rid="bibr33-0961203311430513">33</xref></sup> reported some SCLE patients with lesions resembling erythema annulare centrifugum. In these patients, the active edge of the annular SCLE lesions undergoes vesicular changes followed by squamous-crusted lesions. Vesiculo-bullous changes, associated with focal areas of necrosis upon histology, were present in 38% of the cases reported by Herrero et al.<sup><xref ref-type="bibr" rid="bibr34-0961203311430513">34</xref></sup> In a case reported by Bielsa et al., the annular edges progressed to mimic toxic epidermal necrolysis (TEN).<sup><xref ref-type="bibr" rid="bibr35-0961203311430513">35</xref></sup> Other rare clinical variants include erythroderma,<sup><xref ref-type="bibr" rid="bibr36-0961203311430513">36</xref></sup> vitiligo-like,<sup><xref ref-type="bibr" rid="bibr37-0961203311430513">37</xref></sup> pytiriasis-like<sup><xref ref-type="bibr" rid="bibr38-0961203311430513">38</xref></sup> and generalized poichiloderma.<sup><xref ref-type="bibr" rid="bibr39-0961203311430513">39</xref></sup></p>
<p>Recently, in a series of patients with drug-induced SCLE, in five out of 11 patients annular-polycyclic and targetoid EM-like lesions occurred simultaneously.<sup><xref ref-type="bibr" rid="bibr40-0961203311430513">40</xref></sup></p></sec>
<sec id="sec3-0961203311430513"><title>Erythema multiforme</title>
<p>According to the International Group on Severe Cutaneous Adverse Reactions, EM (including EM minus, EM maius, and mucosal EM) features typical clinical, histopathological and immunopathological findings.<sup><xref ref-type="bibr" rid="bibr5-0961203311430513">5</xref>,<xref ref-type="bibr" rid="bibr41-0961203311430513">41</xref>,<xref ref-type="bibr" rid="bibr42-0961203311430513">42</xref></sup> Most importantly, EM is to be differentiated from ‘acute disseminated epidermal necrolysis’, which includes Stevens–Johnson syndrome (SJS), TEN and the SJS/TEN overlap.<sup><xref ref-type="bibr" rid="bibr42-0961203311430513">42</xref></sup></p>
<p>Often preceded by prodromic symptoms, EM is characterized by the occurrence of several long-lasting, symmetric, typical or atypical raised target lesions on the hands, the feet and the extensor aspects of the limbs.<sup><xref ref-type="bibr" rid="bibr43-0961203311430513">43</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr45-0961203311430513">45</xref></sup></p>
<p>Typical targets were defined as individual lesions measuring less than 3 cm in diameter with a regular round shape, a well-defined border and at least three different zones, that is, two concentric rings around a central disk. One ring consists of palpable oedema, paler than the central disk.<sup><xref ref-type="bibr" rid="bibr40-0961203311430513">40</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr45-0961203311430513">45</xref></sup></p>
<p>Atypical raised targets were defined as round, oedematous palpable lesions, resembling typical targets but with only two zones and/or poorly-defined borders.<sup><xref ref-type="bibr" rid="bibr40-0961203311430513">40</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr42-0961203311430513">42</xref></sup></p>
<p>By contrast, atypical flat targets (which are characteristic of SJS) were defined as round lesions resembling those of EM but with only two zones and/or a poorly-defined border, that are not palpable with the exception of a potentially present central blister.<sup><xref ref-type="bibr" rid="bibr40-0961203311430513">40</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr45-0961203311430513">45</xref></sup></p>
<p>Mucosal lesions, which are absent in EM minus and always present in EM maius, are most often limited to the oral cavity (lips, non-attached gingivae and the ventral side of the tongue), and consist of erosions with fibrin deposits. Intact vesicles or blisters are rarely seen.<sup><xref ref-type="bibr" rid="bibr46-0961203311430513">46</xref></sup></p>
<p>Mucosal EM, also called ectodermosis pluriorificialis, is a rare condition characterized by severe involvement of two or three mucosal sites in the absence of skin lesions.<sup><xref ref-type="bibr" rid="bibr42-0961203311430513">42</xref></sup></p>
<p>EM is considered a relatively common disease, but its real incidence is not known. It occurs in patients of all ages, but mostly in adolescents and young adults, with a slight male predominance (male to female ratio = 3 : 2).<sup><xref ref-type="bibr" rid="bibr5-0961203311430513">5</xref>,<xref ref-type="bibr" rid="bibr43-0961203311430513">43</xref></sup> Genetic predisposition has been reported, with 66% of EM patients featuring the HLA-DQB1*0301 allele (which is present in only 31% of healthy subjects).<sup><xref ref-type="bibr" rid="bibr47-0961203311430513">47</xref></sup></p>
<p>Most cases of EM are related to infections, herpes virus definitely being the most common cause.<sup><xref ref-type="bibr" rid="bibr48-0961203311430513">48</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr50-0961203311430513">50</xref></sup> Mycoplasma pneumoniae is the second major cause of EM and may even be the most frequent aetiologic agent in paediatric cases.<sup><xref ref-type="bibr" rid="bibr51-0961203311430513">51</xref>,<xref ref-type="bibr" rid="bibr52-0961203311430513">52</xref></sup> Many other infections (bacterial or viral: varicella-zoster virus, parvovirus B19, hepatitis B and C viruses, Epstein-Barr virus) have been reported in individual cases or small series, but the evidence for these agents is only circumstantial.<sup><xref ref-type="bibr" rid="bibr53-0961203311430513">53</xref></sup> Drugs are rare causes of EM, and are believed to induce only cases with mucous membrane lesions.<sup><xref ref-type="bibr" rid="bibr44-0961203311430513">44</xref>,<xref ref-type="bibr" rid="bibr53-0961203311430513">53</xref></sup></p></sec>
<sec id="sec4-0961203311430513"><title>Rowell’s syndrome: review of the literature</title>
<p>To date, 71 patients with RS have been described.<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref>,<xref ref-type="bibr" rid="bibr6-0961203311430513">6</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr8-0961203311430513">8</xref>,<xref ref-type="bibr" rid="bibr54-0961203311430513">54</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr88-0961203311430513">88</xref></sup> The most relevant features of such cases are reported in <xref ref-type="table" rid="table1-0961203311430513">Table 1</xref>.
<table-wrap id="table1-0961203311430513" position="float"><label>Table 1</label><caption><p>Clinical and immunological features of the cases reported in the literature as RS since the first description by Rowell et al. in 1963</p></caption>
<graphic alternate-form-of="table1-0961203311430513" xlink:href="10.1177_0961203311430513-table1a.tif"/>
<graphic alternate-form-of="table1-0961203311430513" xlink:href="10.1177_0961203311430513-table1b.tif"/>
<graphic alternate-form-of="table1-0961203311430513" xlink:href="10.1177_0961203311430513-table1c.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Author (reference)</th>
<th>Case no./sex</th>
<th>Age</th>
<th>Type</th>
<th>Perniosis (chilblain)</th>
<th>ANA</th>
<th>RF</th>
<th>Other antibodies</th>
<th>Provoking factors</th>
<th>Mucosal involvement</th></tr></thead>
<tbody align="left">
<tr>
<td>Rowell et al.<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup></td>
<td>1/F</td>
<td>48</td>
<td>DLE</td>
<td>+</td>
<td>Sp 1/256</td>
<td>+</td>
<td>Anti-SjT</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Rowell et al.<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup></td>
<td>2/F</td>
<td>72</td>
<td>DLE</td>
<td>+</td>
<td>Sp 1/16</td>
<td>+</td>
<td>Anti-SjT</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Rowell et al.<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup></td>
<td>3/F</td>
<td>32</td>
<td>DLE</td>
<td>+</td>
<td>Sp 1/1000</td>
<td>+</td>
<td>Anti-SjT</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Rowell et al.<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup></td>
<td>4/F</td>
<td>31</td>
<td>DLE</td>
<td>+</td>
<td>Sp 1/256</td>
<td>+</td>
<td>Anti-SjT</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td align="justify">Jablonska et al.<sup><xref ref-type="bibr" rid="bibr54-0961203311430513">54</xref></sup></td>
<td align="justify">5–16/10F, 2M</td>
<td>19–48 (range)</td>
<td align="justify">SLE (11 p. with unspecified cutaneous lesions, 1 without cutaneous lesions)</td>
<td>–</td>
<td>1/80–1/5120 (range)<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref></sup></td>
<td>NR</td>
<td>NR</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td align="justify">Jablonska et al.<sup><xref ref-type="bibr" rid="bibr54-0961203311430513">54</xref></sup></td>
<td align="justify">17–24/6F, 2M</td>
<td align="justify">13–33 (range)</td>
<td>DLE</td>
<td>–</td>
<td>Only 1 p. 1/120<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref></sup></td>
<td>NR</td>
<td>NR</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Sanchez et al.<sup><xref ref-type="bibr" rid="bibr55-0961203311430513">55</xref></sup></td>
<td>25/F</td>
<td>28</td>
<td>SLE (unspecified)</td>
<td>–</td>
<td>Hom<sup><xref ref-type="table-fn" rid="table-fn3-0961203311430513">b</xref></sup></td>
<td>–</td>
<td>NR</td>
<td>Sun exposure</td>
<td>–</td></tr>
<tr>
<td>Fabbri et al.<sup><xref ref-type="bibr" rid="bibr56-0961203311430513">56</xref></sup></td>
<td>26/F</td>
<td>33</td>
<td>DLE</td>
<td>–</td>
<td>Hom 1/20</td>
<td>–</td>
<td>NR</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Fabbri et al.<sup><xref ref-type="bibr" rid="bibr56-0961203311430513">56</xref></sup></td>
<td>27/F</td>
<td>60</td>
<td>DLE</td>
<td>–</td>
<td>Hom 1/20</td>
<td>–</td>
<td>NR</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Lawrence et al.<sup><xref ref-type="bibr" rid="bibr57-0961203311430513">57</xref></sup></td>
<td>28/F</td>
<td>22</td>
<td>DLE</td>
<td>–</td>
<td>Sp 1/512</td>
<td>–</td>
<td>NR</td>
<td>Mepacrine</td>
<td>Lips, hard palate</td></tr>
<tr>
<td>Lawrence et al.<sup><xref ref-type="bibr" rid="bibr57-0961203311430513">57</xref></sup></td>
<td>29/F</td>
<td>32</td>
<td>DLE</td>
<td>–</td>
<td>Sp 1/640</td>
<td>–</td>
<td>ENA 1/8</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Heyl and Meyer<sup><xref ref-type="bibr" rid="bibr58-0961203311430513">58</xref></sup></td>
<td>30/F</td>
<td>25</td>
<td>SLE fulminate type (without cutaneous lesions)</td>
<td>–</td>
<td>Sp 1/640, Hom 1/20</td>
<td>–</td>
<td>NR</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Crickx et al.<sup><xref ref-type="bibr" rid="bibr59-0961203311430513">59</xref></sup></td>
<td>31/M</td>
<td>53</td>
<td>DLE</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Chapman<sup><xref ref-type="bibr" rid="bibr60-0961203311430513">60</xref></sup></td>
<td>32/F</td>
<td>66</td>
<td>SLE (drug induced, without specific cutaneous lesions)</td>
<td>–</td>
<td>Sp 1/5120</td>
<td>NR</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>Nitrofurantoin</td>
<td>Lips</td></tr>
<tr>
<td>Lewis-Jones et al.<sup><xref ref-type="bibr" rid="bibr61-0961203311430513">61</xref></sup></td>
<td>33/M</td>
<td>62</td>
<td>SLE (malar rash)</td>
<td>–</td>
<td>Sp, 50 IU/mL</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>Doxycycline</td>
<td>Lips, oral mucosa, eyes</td></tr>
<tr>
<td>Parodi et al.<sup><xref ref-type="bibr" rid="bibr6-0961203311430513">6</xref></sup></td>
<td>34/M</td>
<td>62</td>
<td>DLE</td>
<td>+</td>
<td>Sp 1/160</td>
<td>–</td>
<td>Anti-Ro/SSA</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Fiallo et al.<sup><xref ref-type="bibr" rid="bibr62-0961203311430513">62</xref></sup></td>
<td>35/M</td>
<td>18</td>
<td>SLE (annular erythematous lesions of the face and the neck)</td>
<td>? Acro– cyanosis</td>
<td>Hom 1/2560</td>
<td>+</td>
<td>Anti-La/SSB</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Fitzgerald et al.<sup><xref ref-type="bibr" rid="bibr63-0961203311430513">63</xref></sup></td>
<td>36/F</td>
<td>47</td>
<td>SLE (malar rash)</td>
<td>+</td>
<td>Sp 1/640</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Chua et al.<sup><xref ref-type="bibr" rid="bibr64-0961203311430513">64</xref></sup></td>
<td>37/F</td>
<td>9</td>
<td>SLE (facial rash + histiocytic necrotic lymphadenitis)</td>
<td>–</td>
<td>Sp 1/640</td>
<td>NR</td>
<td>Anti-dsDNA</td>
<td>–</td>
<td>Lips, oral mucosa</td></tr>
<tr>
<td>Mendonca<sup><xref ref-type="bibr" rid="bibr65-0961203311430513">65</xref></sup></td>
<td>38/F</td>
<td>68</td>
<td>SLE (annular purpuric erythematous plaques)</td>
<td>+</td>
<td>Sp 1/640</td>
<td>–</td>
<td>Anti-La/SSB, anti-dsDNA</td>
<td>Captopril, furosemide</td>
<td>Lips</td></tr>
<tr>
<td>Child et al.<sup><xref ref-type="bibr" rid="bibr66-0961203311430513">66</xref></sup></td>
<td>39/F</td>
<td>29</td>
<td>SCLE? (scaly plaques on arms and thighs)</td>
<td>+</td>
<td>Sp<sup><xref ref-type="table-fn" rid="table-fn3-0961203311430513">b</xref></sup></td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Marzano et al.<sup><xref ref-type="bibr" rid="bibr67-0961203311430513">67</xref></sup></td>
<td>40/F</td>
<td>32</td>
<td>SLE (erythematous rash of the malar area with necrotic crusting)</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>Anti-Ro/SSA, Anti-Scl70, Lac</td>
<td>–</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Shteyngarts et al.<sup><xref ref-type="bibr" rid="bibr7-0961203311430513">7</xref></sup></td>
<td>41/F</td>
<td>34</td>
<td>SLE (without specific cutaneous lesions)</td>
<td>–</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Phenolphthalein</td>
<td>Lips, tongue</td></tr>
<tr>
<td>Morand et al.<sup><xref ref-type="bibr" rid="bibr68-0961203311430513">68</xref></sup></td>
<td>42/F</td>
<td>28</td>
<td>DLE</td>
<td>–</td>
<td>Sp 1/200</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Morand et al.<sup><xref ref-type="bibr" rid="bibr68-0961203311430513">68</xref></sup></td>
<td>43/F</td>
<td>87</td>
<td>SLE (malar rash)</td>
<td>–</td>
<td>1/5200<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref></sup></td>
<td>+</td>
<td>Anti-Ro/SSA, anti-dsDNA</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Dogra et al.<sup><xref ref-type="bibr" rid="bibr69-0961203311430513">69</xref></sup></td>
<td>44/M</td>
<td>65</td>
<td>SLE (malar rash +  erythematous scaly plaques on the trunk and limbs)</td>
<td>+</td>
<td>+<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref>,<xref ref-type="table-fn" rid="table-fn3-0961203311430513">b</xref></sup></td>
<td>+</td>
<td>NR</td>
<td>–</td>
<td>Oral ulcers</td></tr>
<tr>
<td>Zeitouni et al.<sup><xref ref-type="bibr" rid="bibr70-0961203311430513">70</xref></sup></td>
<td>45/F</td>
<td>41</td>
<td>SCLE? (annular photodistributed lesions)</td>
<td>–</td>
<td>Sp (1/320)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Zeitouni et al.<sup><xref ref-type="bibr" rid="bibr70-0961203311430513">70</xref></sup></td>
<td>46/F</td>
<td>59</td>
<td>SLE (without specific cutaneous lesions)</td>
<td>–</td>
<td>Sp 1/320</td>
<td>–</td>
<td>Anti-Ro/SSA</td>
<td>–</td>
<td align="justify">Oral/vulvar mucosa</td></tr>
<tr>
<td>Roustan et al.<sup><xref ref-type="bibr" rid="bibr8-0961203311430513">8</xref></sup></td>
<td>47/F</td>
<td>27</td>
<td>SLE (malar rash)  + SCLE?</td>
<td>+</td>
<td>Sp 1/640</td>
<td>–</td>
<td>–</td>
<td>Hydroxychloroquine?</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Ramlogan and Tan<sup><xref ref-type="bibr" rid="bibr71-0961203311430513">71</xref></sup></td>
<td>48/F</td>
<td>7</td>
<td>SLE (unspecified)</td>
<td>–</td>
<td>Hom 1/160</td>
<td>–</td>
<td>–</td>
<td>Acyclovir</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Mandelcom and Shear<sup><xref ref-type="bibr" rid="bibr72-0961203311430513">72</xref></sup></td>
<td>59/F</td>
<td>42</td>
<td>SLE (malar rash)  + TEN</td>
<td>–</td>
<td>Hom 1/2560</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>–</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Mandelcom and Shear<sup><xref ref-type="bibr" rid="bibr72-0961203311430513">72</xref></sup></td>
<td>50/F</td>
<td>76</td>
<td>SLE (without cutaneous lesions) + TEN</td>
<td>–</td>
<td>Sp 1/320 Hom 1/160</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>Enalapril/ranitidine</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Pandhi et al.<sup><xref ref-type="bibr" rid="bibr73-0961203311430513">73</xref></sup></td>
<td>51/F</td>
<td>27</td>
<td>SLE/DLE (malar rash, cicatricial alopecia)</td>
<td>–</td>
<td>Sp 1/160</td>
<td>+</td>
<td>Anti-RNP, APL</td>
<td>–</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Aydogan et al.<sup><xref ref-type="bibr" rid="bibr74-0961203311430513">74</xref></sup></td>
<td>52/F</td>
<td>64</td>
<td>SLE (malar rash  + vasculitis) + SS</td>
<td>–</td>
<td>Sp 1/5120 Hom 1/5120</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB, anti-histone, anti-dsDNA</td>
<td>Naproxen, alendronate, Prazosin HCl</td>
<td>–</td></tr>
<tr>
<td>Aydogan et al.<sup><xref ref-type="bibr" rid="bibr74-0961203311430513">74</xref></sup></td>
<td>53/F</td>
<td>51</td>
<td>SLE (without specific cutaneous lesions)</td>
<td>+</td>
<td>Sp 1/320 Hom 1/320</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB, anti-Scl70, anti-dsDNA</td>
<td>Sertraline, paroxetine hydroxychloroquine</td>
<td>Lips</td></tr>
<tr>
<td>Khandpur et al.<sup><xref ref-type="bibr" rid="bibr75-0961203311430513">75</xref></sup></td>
<td>54/F</td>
<td>25</td>
<td>SLE (malar rash)</td>
<td>–</td>
<td>Sp 1/80</td>
<td>+</td>
<td>Anti-dsDNA</td>
<td>–</td>
<td>Oral ulcerations</td></tr>
<tr>
<td>Khandpur et al.<sup><xref ref-type="bibr" rid="bibr75-0961203311430513">75</xref></sup></td>
<td>55/F</td>
<td>29</td>
<td>SLE (without specific cutaneous lesions)</td>
<td>–</td>
<td>Sp + Hom 1/80</td>
<td>+</td>
<td>Anti-dsDNA</td>
<td>–</td>
<td>Lips, oral mucosa</td></tr>
<tr>
<td>Taalauche et al.<sup><xref ref-type="bibr" rid="bibr76-0961203311430513">76</xref></sup></td>
<td>56/F</td>
<td>35</td>
<td>SLE (without specific cutaneous lesions)</td>
<td>–</td>
<td>+<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref>,<xref ref-type="table-fn" rid="table-fn3-0961203311430513">b</xref></sup></td>
<td>–</td>
<td>Anti-Ro/SSA, anti-dsDNA</td>
<td>Hydroxychloroquine</td>
<td>–</td></tr>
<tr>
<td>Marini et al.<sup><xref ref-type="bibr" rid="bibr77-0961203311430513">77</xref></sup></td>
<td>57/F</td>
<td>20</td>
<td>SLE (bullous)</td>
<td>–</td>
<td>Sp 1/10024</td>
<td>–</td>
<td>Anti-Ro/SSA, anti-dsDNA</td>
<td>–</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Rathisharmila et al.<sup><xref ref-type="bibr" rid="bibr78-0961203311430513">78</xref></sup></td>
<td>58/M</td>
<td>10</td>
<td>SLE (erythematous maculo-papular lesions)</td>
<td>+</td>
<td>Sp<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref></sup></td>
<td>–</td>
<td>Anti-Sm</td>
<td>–</td>
<td align="justify">Oral and conjunctival mucosae</td></tr>
<tr>
<td>Aydin et al.<sup><xref ref-type="bibr" rid="bibr79-0961203311430513">79</xref></sup></td>
<td>59/F</td>
<td>29</td>
<td>SLE (rash on the face)</td>
<td>+</td>
<td>Sp 1/40</td>
<td>+</td>
<td>Anti-Sm, anti-dsDNA</td>
<td>–</td>
<td>Oral ulcers</td></tr>
<tr>
<td>Meller et al.<sup><xref ref-type="bibr" rid="bibr80-0961203311430513">80</xref></sup></td>
<td>60/F</td>
<td>24</td>
<td>SLE (without specific cutaneous lesions)</td>
<td>–</td>
<td>ANA: 10.240<sup><xref ref-type="table-fn" rid="table-fn2-0961203311430513">a</xref></sup></td>
<td>–</td>
<td>Anti-Ro/SSA, anti-dsDNA</td>
<td>–</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Shadid et al.<sup><xref ref-type="bibr" rid="bibr81-0961203311430513">81</xref></sup></td>
<td>61/F</td>
<td>87</td>
<td>SLE + rheumatoid arthritis</td>
<td>–</td>
<td>Hom 1/200</td>
<td>–</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Imed et al.<sup><xref ref-type="bibr" rid="bibr82-0961203311430513">82</xref></sup></td>
<td>62/F</td>
<td>26</td>
<td>SLE (malar rash)</td>
<td>–</td>
<td>Hom 1/6400</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>–</td>
<td>Palatal mucosa</td></tr>
<tr>
<td>Imed et al.<sup><xref ref-type="bibr" rid="bibr82-0961203311430513">82</xref></sup></td>
<td>63/F</td>
<td>20</td>
<td>SLE (malar rash)</td>
<td>–</td>
<td>Hom 1/1320</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB, anti-Sm, anti-dsDNA</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Kacalak-Rzepka et al.<sup><xref ref-type="bibr" rid="bibr83-0961203311430513">83</xref></sup></td>
<td>64/F</td>
<td>51</td>
<td>SLE (facial erythema)</td>
<td>–</td>
<td>Sp 1/5000</td>
<td>+</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>Sodium valproate, sertraline, olanzepine</td>
<td>Oral mucosa</td></tr>
<tr>
<td>Duarte et al.<sup><xref ref-type="bibr" rid="bibr84-0961203311430513">84</xref></sup></td>
<td>65/F</td>
<td>63</td>
<td>SLE (without cutaneous lesions)</td>
<td>–</td>
<td>Sp 1/320</td>
<td>–</td>
<td>Anti-Ro/SSA, anti-dsDNA</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Modi et al.<sup><xref ref-type="bibr" rid="bibr85-0961203311430513">85</xref></sup></td>
<td>66/F</td>
<td>28</td>
<td>SLE/DLE</td>
<td>–</td>
<td>Sp 1/320</td>
<td>NR</td>
<td>Anti-Ro/SSA</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Modi et al.<sup><xref ref-type="bibr" rid="bibr85-0961203311430513">85</xref></sup></td>
<td>67/F</td>
<td>44</td>
<td>SLE/DLE</td>
<td>–</td>
<td>NR</td>
<td>NR</td>
<td>–</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Lee et al.<sup><xref ref-type="bibr" rid="bibr86-0961203311430513">86</xref></sup></td>
<td>68/F</td>
<td>61</td>
<td>SLE (without cutaneous lesions)</td>
<td>+</td>
<td>Sp 1/640</td>
<td>–</td>
<td>Anti-Ro/SSA, anti-La/SSB</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>Reilly et al.<sup><xref ref-type="bibr" rid="bibr87-0961203311430513">87</xref></sup></td>
<td>69/M</td>
<td>14</td>
<td>SLE (erythematous- violaceous annular plaques)</td>
<td>+</td>
<td>Sp 1/160</td>
<td>–</td>
<td>Anti-dsDNA</td>
<td>–</td>
<td>Oral erosions</td></tr>
<tr>
<td>Taylor et al.<sup><xref ref-type="bibr" rid="bibr88-0961203311430513">88</xref></sup></td>
<td>70/F</td>
<td>73</td>
<td>SLE (without cutaneous lesions)</td>
<td>–</td>
<td>Sp 1/640</td>
<td>–</td>
<td>Anti-Ro/SSA, anti-RNP</td>
<td>–</td>
<td>Oral erosions</td></tr>
<tr>
<td>Taylor et al.<sup><xref ref-type="bibr" rid="bibr88-0961203311430513">88</xref></sup></td>
<td>71/F</td>
<td>47</td>
<td>SLE (malar rash)</td>
<td>–</td>
<td>Hom 1/80</td>
<td>–</td>
<td>Anti-Ro/SSA</td>
<td>–</td>
<td>–</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311430513"><p>F: female, M: male, RF: rheumatoid factor, p.: patient, + : positive, –: negative,?: uncertain, NR: not reported, SLE: systemic lupus erythematosus, DLE: discoid LE, SCLE: subacute cutaneous LE, SS: Sjögren’s syndrome, TEN: toxic epidermal necrolysis, Sp: speckled, Hom: homogeneous, APS: antiphospholipid syndrome.</p></fn>
<fn id="table-fn2-0961203311430513"><label>a</label><p>Morphology not defined.</p></fn>
<fn id="table-fn3-0961203311430513"><label>b</label><p>Title not defined.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>As shown in <xref ref-type="table" rid="table2-0961203311430513">Table 2</xref>, the clinical and immunological features reported by Rowell et al. in their first description in 1963 (and then defined as major and minor diagnostic criteria of RS by Zeitouni et al. in 2000<sup><xref ref-type="bibr" rid="bibr70-0961203311430513">70</xref></sup>) are present only in a minority of the cases reported in the literature.
<table-wrap id="table2-0961203311430513" position="float"><label>Table 2</label><caption><p>Frequency of the clinical and immunological criteria in the cases diagnosed as RS</p></caption>
<graphic alternate-form-of="table2-0961203311430513" xlink:href="10.1177_0961203311430513-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>Frequency in Rowell et al. (four patients)<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup></th>
<th>Frequency in all the remaining reported cases (67 patients)<sup><xref ref-type="bibr" rid="bibr6-0961203311430513">6</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr8-0961203311430513">8</xref>,<xref ref-type="bibr" rid="bibr54-0961203311430513">54</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr88-0961203311430513">88</xref></sup></th></tr></thead>
<tbody align="left">
<tr>
<td><bold>Clinical features</bold></td>
<td/>
<td/></tr>
<tr>
<td> DLE lesions</td>
<td>100%</td>
<td>18/54 (33.3%)</td></tr>
<tr>
<td> EP-like lesions</td>
<td>100%</td>
<td>65/67 (97%)<sup><xref ref-type="table-fn" rid="table-fn5-0961203311430513">b</xref></sup></td></tr>
<tr>
<td> Perniosis (chilblain lupus)</td>
<td>100%</td>
<td>10/67 (14.9%)</td></tr>
<tr>
<td><bold>Immunological features</bold></td>
<td/>
<td/></tr>
<tr>
<td> ANA (speckled)</td>
<td>100%</td>
<td>29/48 (60.4%)</td></tr>
<tr>
<td> Ro/SSA<sup><xref ref-type="table-fn" rid="table-fn4-0961203311430513">a</xref></sup></td>
<td>100%<sup><xref ref-type="table-fn" rid="table-fn4-0961203311430513">a</xref></sup></td>
<td>23/39 (59%)</td></tr>
<tr>
<td> La/SSB<sup><xref ref-type="table-fn" rid="table-fn4-0961203311430513">a</xref></sup></td>
<td>100%<sup><xref ref-type="table-fn" rid="table-fn4-0961203311430513">a</xref></sup></td>
<td>14/39 (35.9%)</td></tr>
<tr>
<td> Rheumatoid factor</td>
<td>100%</td>
<td>18/42 (42.9%)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203311430513"><label>a</label><p>Anti-SjT precipitating antibodies to saline extract of human tissue are identical to Ro/SSA, La/SSB antibodies.</p></fn>
<fn id="table-fn5-0961203311430513"><label>b</label><p>Typical annular-polycyclic SCLE lesions were described in two cases<sup><xref ref-type="bibr" rid="bibr20-0961203311430513">20</xref>,<xref ref-type="bibr" rid="bibr36-0961203311430513">36</xref></sup> and an overlap between EM and SJS in one case;<sup><xref ref-type="bibr" rid="bibr35-0961203311430513">35</xref></sup> in two cases, skin lesions clinically suggestive for EM showed histopathological features typical of LE.<sup><xref ref-type="bibr" rid="bibr85-0961203311430513">85</xref></sup></p></fn></table-wrap-foot>
</table-wrap></p>
<p>Instead, in the majority of cases present in the literature, both DLE lesions and perniosis (chilblain lupus), which were two of the main clinical features of the cases reported by Rowell et al.,<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup> are lacking. By contrast, several other types of CLE are reported, including 15 cases of malar rash (which was associated with chronic CLE in one case<sup><xref ref-type="bibr" rid="bibr73-0961203311430513">73</xref></sup>), one case of diffuse maculo-papular rash,<sup><xref ref-type="bibr" rid="bibr78-0961203311430513">78</xref></sup> one case of bullous LE<sup><xref ref-type="bibr" rid="bibr77-0961203311430513">77</xref></sup> and one case of necrotic lesions associated with anti-phospholipid syndrome.<sup><xref ref-type="bibr" rid="bibr67-0961203311430513">67</xref>,<xref ref-type="bibr" rid="bibr73-0961203311430513">73</xref></sup> In other cases, annular-polycyclic SCLE lesions have been described.<sup><xref ref-type="bibr" rid="bibr65-0961203311430513">65</xref>,<xref ref-type="bibr" rid="bibr66-0961203311430513">66</xref>,<xref ref-type="bibr" rid="bibr70-0961203311430513">70</xref></sup> In 13 patients with a diagnosis of SLE, specific CLE lesions were absent, while in 17 patients they were not described or not specific.</p>
<p>Systemic manifestations present in SLE patients included lupus nephritis, serositis (pericarditis) and systemic vasculitis. Furthermore, one case was associated with Sjögren's syndrome,<sup><xref ref-type="bibr" rid="bibr74-0961203311430513">74</xref></sup> one case with rheumatoid arthritis<sup><xref ref-type="bibr" rid="bibr81-0961203311430513">81</xref></sup> and one case with histiocytic necrotizing lymphadenitis.<sup><xref ref-type="bibr" rid="bibr64-0961203311430513">64</xref></sup></p>
<p>With regard to the skin lesions of EM, typical raised targets were reported very rarely, while in several cases the lesions were described as figurate, flat, annular lesions – probably more consistent with the annular-polycyclic variant of SCLE than with EM. Moreover, in the majority of cases an accurate morphological description of the cutaneous lesions was lacking and the clinical photographs, when present, were not of a good quality.</p>
<p>Interestingly, in two cases the lesions were clinically suggestive for SCLE, while the histopathological findings were consistent with EM.<sup><xref ref-type="bibr" rid="bibr73-0961203311430513">73</xref>,<xref ref-type="bibr" rid="bibr84-0961203311430513">84</xref></sup> By contrast, two other cases presented with clinically typical EM lesions, while the histopathological examination revealed the presence of LE features.<sup><xref ref-type="bibr" rid="bibr85-0961203311430513">85</xref></sup> Finally, one of the cases reported was consistent with SJS/TEN overlap syndrome,<sup><xref ref-type="bibr" rid="bibr83-0961203311430513">83</xref></sup> whilst in two cases the initial clinical manifestations were suggestive for EM but, in the following relapses, clinical and histopathological features of TEN were observed.<sup><xref ref-type="bibr" rid="bibr72-0961203311430513">72</xref></sup></p>
<p>All these data suggest the difficulties of clinically distinguishing between the annular-polycyclic type of SCLE and EM, particularly if the EM diagnostic criteria suggested by Assier et al. are not used.<sup><xref ref-type="bibr" rid="bibr5-0961203311430513">5</xref></sup> Furthermore, it is also challenging to differentiate between these two entities on the basis of the histopathological findings. As an example, necrotic keratinocytes can be found not only in EM,<sup><xref ref-type="bibr" rid="bibr74-0961203311430513">74</xref></sup> but also in SCLE skin lesions, as suggested by Herrero et al., who recently reported the presence of this histopathological finding in six out of 13 (54%) SCLE patients.<sup><xref ref-type="bibr" rid="bibr89-0961203311430513">89</xref></sup></p>
<p>Three out of four patients of the original case series by Rowell<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup> lack the histopathological description of EM-like lesions, suggesting that they could have been SCLE patients misdiagnosed as RS. Lyon et al.<sup><xref ref-type="bibr" rid="bibr31-0961203311430513">31</xref></sup> described two cases of SCLE initially diagnosed as RS, with EM-like lesions associated with positive Ro/SSA antibodies and RF, but further histopathological analysis finally suggested the diagnosis of SCLE.</p>
<p>In several cases, direct immunofluorescence (DIF) of the EM-like lesions was performed together with the histopathological examination. Interestingly, in all of the cases of EM associated with LED, DIF was negative<sup><xref ref-type="bibr" rid="bibr54-0961203311430513">54</xref>,<xref ref-type="bibr" rid="bibr56-0961203311430513">56</xref>,<xref ref-type="bibr" rid="bibr59-0961203311430513">59</xref>,<xref ref-type="bibr" rid="bibr62-0961203311430513">62</xref></sup> or showed non-specific findings such as perivascular deposition of Ig,<sup><xref ref-type="bibr" rid="bibr6-0961203311430513">6</xref></sup> whilst in 14 out of 22 cases of EM associated with SLE, junctional deposits of Ig and complement could be found in the EM-like lesions. Thus, DIF findings could represent a diagnostic criterion to differentiate between EM-like and SCLE lesions, since a junctional deposition of Ig and C can be found only in the latter, unless EM is associated with SLE.</p>
<p>The presence of chilblains (considered by Zeitouni et al.<sup><xref ref-type="bibr" rid="bibr70-0961203311430513">70</xref></sup> as a minor diagnostic criterion) was reported only in 14.9% of cases. It has been hypothesized that the presence of speckled ANA may be part of the immunologic features contributing to the formation of chilblain lesions.<sup><xref ref-type="bibr" rid="bibr75-0961203311430513">75</xref></sup> Additionally, most patients with chilblains often showed a positive RF. Therefore, it is possible that both the speckled ANA and the RF are actually associated with perniosis.<sup><xref ref-type="bibr" rid="bibr7-0961203311430513">7</xref>,<xref ref-type="bibr" rid="bibr74-0961203311430513">74</xref></sup> In fact, chilblains are one of the more common cutaneous manifestations in the spectrum of cutaneous LE, and speckled ANA and RF are strongly associated with chilblain lupus variant and should not be considered as specific markers.<sup><xref ref-type="bibr" rid="bibr75-0961203311430513">75</xref></sup></p>
<p>The speckled pattern of ANA, thought to be one of the most consistent immunologic features of RS and reported in 60.4% of patients with RS, is positive also in a significant proportion of SLE, mixed connective tissue disease, and systemic sclerosis patients, so it is not unique to RS.<sup><xref ref-type="bibr" rid="bibr90-0961203311430513">90</xref></sup></p>
<p>RF positivity, always present in the cases described by Rowell et al., was reported only in 42.9% of the following cases from the literature (<xref ref-type="table" rid="table2-0961203311430513">Table 2</xref>). Its presence in DLE (17%), SLE (40%), systemic sclerosis (40%), SCLE, and Sjögren’s syndrome also disclaims its uniqueness to RS.<sup><xref ref-type="bibr" rid="bibr91-0961203311430513">91</xref></sup></p>
<p>The same stands for anti-Ro/SSA antibodies, which were found in 59% of the patients with RS, but have been detected in 60–90% of SCLE patients, and also in Sjögren’s syndrome, rheumatoid arthritis and systemic sclerosis; furthermore, they are strongly associated with photosensitivity and vasculitis in SLE.<sup><xref ref-type="bibr" rid="bibr92-0961203311430513">92</xref></sup></p></sec>
<sec id="sec5-0961203311430513" sec-type="conclusions"><title>Conclusions</title>
<p>In conclusion, based on our own experience<sup><xref ref-type="bibr" rid="bibr44-0961203311430513">44</xref></sup> and on an accurate review of the literature, we observed that, in the majority of cases, different entities were reported under the name of RS. In particular, patients with an association between SCLE annular-polycyclic type and DLE or ACLE (malar rash or, less frequently, maculo-papular rash or bullous rash) were incorrectly diagnosed as having RS.</p>
<p>Thus, according with other authors,<sup><xref ref-type="bibr" rid="bibr8-0961203311430513">8</xref>,<xref ref-type="bibr" rid="bibr66-0961203311430513">66</xref>,<xref ref-type="bibr" rid="bibr74-0961203311430513">74</xref>,<xref ref-type="bibr" rid="bibr84-0961203311430513">84</xref>,<xref ref-type="bibr" rid="bibr93-0961203311430513">93</xref></sup> we suggest that LE with EM-like rashes represents a subset of SCLE with targetoid lesions rather than a distinct entity.</p>
<p>A real association between DLE and EM was present only in a minority of cases (about 20 patients) and could be considered a mere coincidence without any immunopathological implication or unusual characteristic to either illness. As for other associations, for example those between CLE and lichen planus or psoriasis, the coexistence of CLE and EM does not justify the framing of a separate syndrome as originally suggested by Rowell et al.<sup><xref ref-type="bibr" rid="bibr1-0961203311430513">1</xref></sup></p></sec>
<sec id="sec6-0961203311430513"><title>Conflict of interest statement</title>
<p>None.</p></sec>
<sec id="sec7-0961203311430513"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311430513"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rowell</surname><given-names>NR</given-names></name><name><surname>Beck</surname><given-names>JS</given-names></name><name><surname>Anderson</surname><given-names>JR</given-names></name></person-group>. <article-title>Lupus erythematosus and erythema multiforme-like lesions. A syndrome with characteristic immunological abnormalities</article-title>. <source>Arch Dermatol</source> <year>1963</year>; <volume>88</volume>: <fpage>176</fpage>–<lpage>180</lpage>.</citation></ref>
<ref id="bibr2-0961203311430513"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herrera-Esparza</surname><given-names>R</given-names></name><name><surname>Halim</surname><given-names>HY</given-names></name><name><surname>Provost</surname><given-names>TT</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names></name></person-group>. <article-title>A sensitive and specific assay to detect Ro(SS-A) and La(SS-B) antibodies</article-title>. <source>J Invest Dermatol</source> <year>1986</year>; <volume>86</volume>: <fpage>217</fpage>–<lpage>221</lpage>.</citation></ref>
<ref id="bibr3-0961203311430513"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilliam</surname><given-names>JT</given-names></name></person-group>. <article-title>The cutaneous sign of lupus erythematosus</article-title>. <source>Cont Educ Fam Phys</source> <year>1977</year>; <volume>6</volume>: <fpage>34</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr4-0961203311430513"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gilliam</surname><given-names>JN</given-names></name><name><surname>Sontheimer</surname><given-names>RD</given-names></name></person-group>. <article-title>Distinctive cutaneous subsets in the spectrum of lupus erythematosus</article-title>. <source>J Am Acad Dermatol</source> <year>1981</year>; <volume>4</volume>: <fpage>471</fpage>–<lpage>475</lpage>.</citation></ref>
<ref id="bibr5-0961203311430513"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assier</surname><given-names>H</given-names></name><name><surname>Bastuji-Garin</surname><given-names>S</given-names></name><name><surname>Revuz</surname><given-names>J</given-names></name><name><surname>Roujeau</surname><given-names>JC</given-names></name></person-group>. <article-title>Erythema multiforme with mucous membrane involvement and Stevens–Johnson syndrome are clinically different disorders with distinct causes</article-title>. <source>Arch Dermatol</source> <year>1995</year>; <volume>131</volume>: <fpage>539</fpage>–<lpage>543</lpage>.</citation></ref>
<ref id="bibr6-0961203311430513"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Drago</surname><given-names>EF</given-names></name><name><surname>Varaldo</surname><given-names>G</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name></person-group>. <article-title>Rowell’s syndrome. Report of a case</article-title>. <source>J Am Acad Dermatol</source> <year>1989</year>; <volume>21</volume>: <fpage>374</fpage>–<lpage>377</lpage>.</citation></ref>
<ref id="bibr7-0961203311430513"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shteyngarts</surname><given-names>AR</given-names></name><name><surname>Warner</surname><given-names>MR</given-names></name><name><surname>Camisa</surname><given-names>C</given-names></name></person-group>. <article-title>Lupus erythematosus associated with erythema multiforme: does Rowell’s syndrome exist?</article-title> <source>J Am Acad Dermatol</source> <year>1999</year>; <volume>40</volume>: <fpage>773</fpage>–<lpage>777</lpage>.</citation></ref>
<ref id="bibr8-0961203311430513"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roustan</surname><given-names>G</given-names></name><name><surname>Salas</surname><given-names>C</given-names></name><name><surname>Barbadillo</surname><given-names>C</given-names></name><name><surname>Sánchez Yus</surname><given-names>E</given-names></name><name><surname>Mulero</surname><given-names>J</given-names></name><name><surname>Simón</surname><given-names>A</given-names></name></person-group>. <article-title>Lupus erythematosus with an erythema multiforme-like eruption</article-title>. <source>Eur J Dermatol</source> <year>2000</year>; <volume>10</volume>: <fpage>459</fpage>–<lpage>462</lpage>.</citation></ref>
<ref id="bibr9-0961203311430513"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontheimer</surname><given-names>RD</given-names></name><name><surname>Thomas</surname><given-names>JR</given-names></name><name><surname>Gilliam</surname><given-names>JN</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset</article-title>. <source>Arch Dermatol</source> <year>1979</year>; <volume>115</volume>: <fpage>1409</fpage>–<lpage>1415</lpage>.</citation></ref>
<ref id="bibr10-0961203311430513"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontheimer</surname><given-names>RD</given-names></name><name><surname>Stastny</surname><given-names>P</given-names></name><name><surname>Gilliam</surname><given-names>JN</given-names></name></person-group>. <article-title>Human histocompatibility antigen associations in subacute cutaneous lupus erythematosus</article-title>. <source>J Clin Invest</source> <year>1981</year>; <volume>67</volume>: <fpage>312</fpage>–<lpage>316</lpage>.</citation></ref>
<ref id="bibr11-0961203311430513"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>Huff</surname><given-names>JC</given-names></name><name><surname>Jones</surname><given-names>SK</given-names></name><name><surname>Orton</surname><given-names>PW</given-names></name><name><surname>Lee</surname><given-names>LA</given-names></name><name><surname>Norris</surname><given-names>DA</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy</article-title>. <source>Ann Intern Med</source> <year>1985</year>; <volume>103</volume>: <fpage>49</fpage>–<lpage>51</lpage>.</citation></ref>
<ref id="bibr12-0961203311430513"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Rencic</surname><given-names>A</given-names></name><name><surname>Diglio</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus</article-title>. <source>Arch Dermatol</source> <year>2003</year>; <volume>139</volume>: <fpage>45</fpage>–<lpage>49</lpage>.</citation></ref>
<ref id="bibr13-0961203311430513"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callen</surname><given-names>JP</given-names></name><name><surname>Hughes</surname><given-names>AP</given-names></name><name><surname>Kulp-Shorten</surname><given-names>C</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases</article-title>. <source>Arch Dermatol</source> <year>2001</year>; <volume>137</volume>: <fpage>1196</fpage>–<lpage>1198</lpage>.</citation></ref>
<ref id="bibr14-0961203311430513"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>MR</given-names></name><name><surname>Crosby</surname><given-names>D</given-names></name></person-group>. <article-title>Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>1665</fpage>–<lpage>1669</lpage>.</citation></ref>
<ref id="bibr15-0961203311430513"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crowson</surname><given-names>AN</given-names></name><name><surname>Magro</surname><given-names>C</given-names></name></person-group>. <article-title>The cutaneous pathology of lupus erythematosus: a review</article-title>. <source>J Cutan Pathol</source> <year>2001</year>; <volume>28</volume>: <fpage>1</fpage>–<lpage>23</lpage>.</citation></ref>
<ref id="bibr16-0961203311430513"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Caproni</surname><given-names>M</given-names></name><name><surname>Cardinali</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus. A review by the Italian group of immunodermatology</article-title>. <source>Dermatology</source> <year>2000</year>; <volume>200</volume>: <fpage>6</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr17-0961203311430513"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardinali</surname><given-names>C</given-names></name><name><surname>Caproni</surname><given-names>M</given-names></name><name><surname>Bernacchi</surname><given-names>E</given-names></name><name><surname>Amato</surname><given-names>L</given-names></name><name><surname>Fabbri</surname><given-names>P</given-names></name></person-group>. <article-title>The spectrum of cutaneous manifestations in lupus erythematosus: The Italian experience</article-title>. <source>Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>413</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr18-0961203311430513"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>A</given-names></name><name><surname>Sonntag</surname><given-names>M</given-names></name><name><surname>Richter-Hintz</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Phototesting in lupus erythematosus: a 15-year experience</article-title>. <source>J Am Acad Dermatol</source> <year>2001</year>; <volume>45</volume>: <fpage>86</fpage>–<lpage>95</lpage>.</citation></ref>
<ref id="bibr19-0961203311430513"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Millard</surname><given-names>TP</given-names></name><name><surname>Hawk</surname><given-names>JL</given-names></name><name><surname>McGregor</surname><given-names>JM</given-names></name></person-group>. <article-title>Photosensitivity in lupus</article-title>. <source>Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>3</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr20-0961203311430513"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontheimer</surname><given-names>RD</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus: a decade's perspective</article-title>. <source>Med Clin North Am</source> <year>1989</year>; <volume>73</volume>: <fpage>1073</fpage>–<lpage>1090</lpage>.</citation></ref>
<ref id="bibr21-0961203311430513"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>KM</given-names></name><name><surname>Thorton</surname><given-names>JC</given-names></name><name><surname>Davis</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Morbidity and mortality in patients with subacute cutaneous lupus erythematosus</article-title>. <source>J Invest Dermatol</source> <year>1984</year>; <volume>82</volume>: <fpage>408</fpage>–<lpage>409</lpage>.</citation></ref>
<ref id="bibr22-0961203311430513"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>P</given-names></name><name><surname>Cardinali</surname><given-names>C</given-names></name><name><surname>Giomi</surname><given-names>B</given-names></name><name><surname>Caproni</surname><given-names>M</given-names></name></person-group>. <article-title>Cutaneous lupus erythematosus: diagnosis and management</article-title>. <source>Am J Clin Dermatol</source> <year>2003</year>; <volume>4</volume>: <fpage>449</fpage>–<lpage>465</lpage>.</citation></ref>
<ref id="bibr23-0961203311430513"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callen</surname><given-names>JP</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients</article-title>. <source>Arthritis Rheum</source> <year>1988</year>; <volume>31</volume>: <fpage>1007</fpage>–<lpage>1013</lpage>.</citation></ref>
<ref id="bibr24-0961203311430513"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vera-Recabarren</surname><given-names>MA</given-names></name><name><surname>García-Carrasco</surname><given-names>M</given-names></name><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Herrero</surname><given-names>C</given-names></name></person-group>. <article-title>Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients</article-title>. <source>Br J Dermatol</source> <year>2010</year>; <volume>162</volume>: <fpage>91</fpage>–<lpage>101</lpage>.</citation></ref>
<ref id="bibr25-0961203311430513"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LA</given-names></name><name><surname>Roberts</surname><given-names>CM</given-names></name><name><surname>Frank</surname><given-names>MB</given-names></name><name><surname>McCubbin</surname><given-names>VR</given-names></name><name><surname>Reichlin</surname><given-names>M</given-names></name></person-group>. <article-title>The autoantibody response to Ro/SSA in cutaneous lupus erythematosus</article-title>. <source>Arch Dermatol</source> <year>1994</year>; <volume>130</volume>: <fpage>1262</fpage>–<lpage>1268</lpage>.</citation></ref>
<ref id="bibr26-0961203311430513"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansson-Stephansson</surname><given-names>E</given-names></name><name><surname>Koskimies</surname><given-names>S</given-names></name><name><surname>Partanen</surname><given-names>J</given-names></name><name><surname>Kariniemi</surname><given-names>AL</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus. Genetic markers and clinical and immunological findings in patients</article-title>. <source>Arch Dermatol</source> <year>1989</year>; <volume>125</volume>: <fpage>791</fpage>–<lpage>796</lpage>.</citation></ref>
<ref id="bibr27-0961203311430513"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Chetrit</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>EK</given-names></name><name><surname>Sullivan</surname><given-names>KF</given-names></name><name><surname>Tan</surname><given-names>EM</given-names></name></person-group>. <article-title>A 52-kD protein is a novel component of the SS-A/Ro antigenic particle</article-title>. <source>J Exp Med</source> <year>1988</year>; <volume>167</volume>: <fpage>1560</fpage>–<lpage>1571</lpage>.</citation></ref>
<ref id="bibr28-0961203311430513"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boire</surname><given-names>G</given-names></name><name><surname>Craft</surname><given-names>J</given-names></name></person-group>. <article-title>Biochemical and immunological heterogeneity of the Ro ribonucleoprotein particles. Analysis with sera specific for the RohY5 particle</article-title>. <source>J Clin Invest</source> <year>1989</year>; <volume>84</volume>: <fpage>270</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr29-0961203311430513"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chlebus</surname><given-names>E</given-names></name><name><surname>Wolska</surname><given-names>H</given-names></name><name><surname>Blaszczyk</surname><given-names>M</given-names></name><name><surname>Jablonska</surname><given-names>S</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications</article-title>. <source>J Am Acad Dermatol</source> <year>1998</year>; <volume>38</volume>: <fpage>405</fpage>–<lpage>412</lpage>.</citation></ref>
<ref id="bibr30-0961203311430513"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Massone</surname><given-names>C</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name></person-group>. <article-title>Erythema multiforme-like subacute cutaneous lupus erythematosus</article-title>. <source>Acta Derm Venereol</source> <year>2000</year>; <volume>80</volume>: <fpage>308</fpage>–<lpage>309</lpage>.</citation></ref>
<ref id="bibr31-0961203311430513"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyon</surname><given-names>CC</given-names></name><name><surname>Blewitt</surname><given-names>R</given-names></name><name><surname>Harrison</surname><given-names>PV</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus: two cases of delayed diagnosis</article-title>. <source>Acta Derm Venereol</source> <year>1998</year>; <volume>78</volume>: <fpage>57</fpage>–<lpage>59</lpage>.</citation></ref>
<ref id="bibr32-0961203311430513"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>JM</given-names></name></person-group>. <article-title>Annular vesicular lupus erythematosus</article-title>. <source>Cutis</source> <year>1981</year>; <volume>28</volume>: <fpage>90</fpage>–<lpage>92</lpage>.</citation></ref>
<ref id="bibr33-0961203311430513"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wechsler</surname><given-names>HL</given-names></name><name><surname>Stavrides</surname><given-names>A</given-names></name></person-group>. <article-title>Systemic lupus erythematosus with anti-Ro antibodies: clinical, histologic and immunologic findings. Report of three cases</article-title>. <source>J Am Acad Dermatol</source> <year>1982</year>; <volume>6</volume>: <fpage>73</fpage>–<lpage>83</lpage>.</citation></ref>
<ref id="bibr34-0961203311430513"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herrero</surname><given-names>C</given-names></name><name><surname>Bielsa</surname><given-names>I</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases</article-title>. <source>J Am Acad Dermatol</source> <year>1988</year>; <volume>19</volume>: <fpage>1057</fpage>–<lpage>1062</lpage>.</citation></ref>
<ref id="bibr35-0961203311430513"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bielsa</surname><given-names>I</given-names></name><name><surname>Herrero</surname><given-names>C</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Mascaró</surname><given-names>JM</given-names></name></person-group>. <article-title>Lupus erythematosus and toxic epidermal necrolysis</article-title>. <source>J Am Acad Dermatol</source> <year>1987</year>; <volume>16</volume>: <fpage>1265</fpage>–<lpage>1267</lpage>.</citation></ref>
<ref id="bibr36-0961203311430513"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeSpain</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>DP</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus presenting as erythroderma</article-title>. <source>J Am Acad Dermatol</source> <year>1988</year>; <volume>19</volume>: <fpage>388</fpage>–<lpage>392</lpage>.</citation></ref>
<ref id="bibr37-0961203311430513"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milde</surname><given-names>P</given-names></name><name><surname>Goerz</surname><given-names>G</given-names></name></person-group>. <article-title>Depigmentierung bei lupus erythematodes Klinischer ‘clue’ zum Subakut lupus erythematodes (SCLE)</article-title>. <source>Z Hautkr</source> <year>1994</year>; <volume>69</volume>: <fpage>123</fpage>–<lpage>126</lpage>.</citation></ref>
<ref id="bibr38-0961203311430513"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caproni</surname><given-names>M</given-names></name><name><surname>Cardinali</surname><given-names>C</given-names></name><name><surname>Salvatore</surname><given-names>E</given-names></name><name><surname>Fabbri</surname><given-names>P</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus with pityriasis-like cutaneous manifestations</article-title>. <source>Int J Dermatol</source> <year>2001</year>; <volume>40</volume>: <fpage>59</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr39-0961203311430513"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pramatarov</surname><given-names>K</given-names></name><name><surname>Vassileva</surname><given-names>S</given-names></name><name><surname>Miteva</surname><given-names>L</given-names></name></person-group>. <article-title>Subacute cutaneous lupus erythematosus presenting with generalized poikiloderma</article-title>. <source>J Am Acad Dermatol</source> <year>2000</year>; <volume>42</volume>: <fpage>286</fpage>–<lpage>288</lpage>.</citation></ref>
<ref id="bibr40-0961203311430513"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marzano</surname><given-names>AV</given-names></name><name><surname>Lazzari</surname><given-names>R</given-names></name><name><surname>Polloni</surname><given-names>I</given-names></name><name><surname>Crosti</surname><given-names>C</given-names></name><name><surname>Fabbri</surname><given-names>P</given-names></name><name><surname>Cugno</surname><given-names>M</given-names></name></person-group>. <article-title>Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart</article-title>. <source>Br J Dermatol</source> <year>2011</year>; <volume>165</volume>: <fpage>335</fpage>–<lpage>341</lpage>.</citation></ref>
<ref id="bibr41-0961203311430513"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bastuji-Garin</surname><given-names>S</given-names></name><name><surname>Rzany</surname><given-names>B</given-names></name><name><surname>Stern</surname><given-names>RS</given-names></name><name><surname>Shear</surname><given-names>NH</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Roujeau</surname><given-names>JC</given-names></name></person-group>. <article-title>Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme</article-title>. <source>Arch Dermatol</source> <year>1993</year>; <volume>129</volume>: <fpage>92</fpage>–<lpage>96</lpage>.</citation></ref>
<ref id="bibr42-0961203311430513"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auquier-Dunant</surname><given-names>A</given-names></name><name><surname>Mockenhaupt</surname><given-names>M</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Correia</surname><given-names>O</given-names></name><name><surname>Schröder</surname><given-names>W</given-names></name><name><surname>Roujeau</surname><given-names>JC</given-names></name></person-group>. <collab>SCAR Study Group (Severe Cutaneous Adverse Reactions)</collab>. <article-title>Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study</article-title>. <source>Arch Dermatol</source> <year>2002</year>; <volume>138</volume>: <fpage>1019</fpage>–<lpage>1024</lpage>.</citation></ref>
<ref id="bibr43-0961203311430513"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brice</surname><given-names>SL</given-names></name><name><surname>Huff</surname><given-names>JC</given-names></name><name><surname>Weston</surname><given-names>WL</given-names></name></person-group>. <article-title>Erythema multiforme minor in children</article-title>. <source>Pediatrician</source> <year>1991</year>; <volume>11</volume>: <fpage>3</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr44-0961203311430513"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>P</given-names></name><name><surname>Panconesi</surname><given-names>E</given-names></name></person-group>. <article-title>Erythema multiforme (‘minus’ and ‘maius’) and drug intake</article-title>. <source>Clin Dermatol</source> <year>1993</year>; <volume>11</volume>: <fpage>479</fpage>–<lpage>490</lpage>.</citation></ref>
<ref id="bibr45-0961203311430513"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huff</surname><given-names>JC</given-names></name><name><surname>Weston</surname><given-names>WL</given-names></name></person-group>. <article-title>Recurrent erythema multiforme</article-title>. <source>Medicine (Baltimore)</source> <year>1989</year>; <volume>68</volume>: <fpage>133</fpage>–<lpage>140</lpage>.</citation></ref>
<ref id="bibr46-0961203311430513"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farthing</surname><given-names>PM</given-names></name><name><surname>Maragou</surname><given-names>P</given-names></name><name><surname>Coates</surname><given-names>M</given-names></name><name><surname>Tatnall</surname><given-names>F</given-names></name><name><surname>Leigh</surname><given-names>IM</given-names></name><name><surname>Williams</surname><given-names>DM</given-names></name></person-group>. <article-title>Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme</article-title>. <source>J Oral Pathol Med</source> <year>1995</year>; <volume>24</volume>: <fpage>9</fpage>–<lpage>13</lpage>.</citation></ref>
<ref id="bibr47-0961203311430513"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>I</given-names></name><name><surname>Lepage</surname><given-names>V</given-names></name><name><surname>Douay</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>HLA DQB1*0301 allele is involved in the susceptibility to erythema multiforme</article-title>. <source>J Invest Dermatol</source> <year>1991</year>; <volume>97</volume>: <fpage>697</fpage>–<lpage>700</lpage>.</citation></ref>
<ref id="bibr48-0961203311430513"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>WL</given-names></name><name><surname>Brice</surname><given-names>SL</given-names></name><name><surname>Jester</surname><given-names>JD</given-names></name><name><surname>Lane</surname><given-names>AT</given-names></name><name><surname>Stockert</surname><given-names>S</given-names></name><name><surname>Huff</surname><given-names>JC</given-names></name></person-group>. <article-title>Herpes simplex virus in childhood erythema multiforme</article-title>. <source>Pediatrics</source> <year>1992</year>; <volume>89</volume>: <fpage>32</fpage>–<lpage>34</lpage>.</citation></ref>
<ref id="bibr49-0961203311430513"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>WL</given-names></name><name><surname>Morelli</surname><given-names>JG</given-names></name></person-group>. <article-title>Herpes simplex virus-associated erythema multiforme in prepubertal children</article-title>. <source>Arch Pediatr Adolesc Med</source> <year>1997</year>; <volume>151</volume>: <fpage>1014</fpage>–<lpage>1018</lpage>.</citation></ref>
<ref id="bibr50-0961203311430513"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schofield</surname><given-names>JK</given-names></name><name><surname>Tatnall</surname><given-names>FM</given-names></name><name><surname>Leigh</surname><given-names>IM</given-names></name></person-group>. <article-title>Recurrent erythema multiforme: clinical features and treatment in a large series of patients</article-title>. <source>Br J Dermatol</source> <year>1993</year>; <volume>128</volume>: <fpage>542</fpage>–<lpage>545</lpage>.</citation></ref>
<ref id="bibr51-0961203311430513"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Léauté-Labrèze</surname><given-names>C</given-names></name><name><surname>Lamireau</surname><given-names>T</given-names></name><name><surname>Chawki</surname><given-names>D</given-names></name><name><surname>Maleville</surname><given-names>J</given-names></name><name><surname>Taïeb</surname><given-names>A</given-names></name></person-group>. <article-title>Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome</article-title>. <source>Arch Dis Child</source> <year>2000</year>; <volume>83</volume>: <fpage>347</fpage>–<lpage>352</lpage>.</citation></ref>
<ref id="bibr52-0961203311430513"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>NS</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>LC</given-names></name><name><surname>Lin</surname><given-names>YT</given-names></name><name><surname>Chiang</surname><given-names>BL</given-names></name></person-group>. <article-title>Clinical characteristics of childhood erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in Taiwanese children</article-title>. <source>J Microbiol Immunol Infect</source> <year>2004</year>; <volume>37</volume>: <fpage>366</fpage>–<lpage>373</lpage>.</citation></ref>
<ref id="bibr53-0961203311430513"><label>53</label><citation citation-type="other"><comment>Roujeau JC. Erythema multiforme. In: Wolff K, Goldsmith LA, Kats S, Gilchrest BA, Paller AS, Leffel DJ (eds) Fitzpatrick's dermatology in general medicine, 7th edn. McGraw-Hill, New York, USA 2007, 343–349</comment>.</citation></ref>
<ref id="bibr54-0961203311430513"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jablonska</surname><given-names>S</given-names></name><name><surname>Blaszczyk</surname><given-names>M</given-names></name><name><surname>Chorzelski</surname><given-names>T</given-names></name></person-group>. <article-title>Syndrome de Rowell: lupus erythemateux avec des lesions co-existantes de type erytheme polymorphe bulleux</article-title>. <source>Med Hyg</source> <year>1972</year>; <volume>30</volume>: <fpage>1390</fpage>–<lpage>1394</lpage>.</citation></ref>
<ref id="bibr55-0961203311430513"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sánchez</surname><given-names>M</given-names></name><name><surname>Cruces</surname><given-names>J</given-names></name><name><surname>Fonseca</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus with skin manifestations of exudative erythema multiforme</article-title>. <source>Actas Dermosifiliogr</source> <year>1975</year>; <volume>66</volume>: <fpage>631</fpage>–<lpage>638</lpage>.</citation></ref>
<ref id="bibr56-0961203311430513"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>P</given-names></name><name><surname>Panconesi</surname><given-names>E</given-names></name></person-group>. <article-title>Rowell's syndrome. Clinical and immunopathological study of 2 cases</article-title>. <source>Ann Dermatol Syphiligr</source> <year>1975</year>; <volume>102</volume>: <fpage>405</fpage>–<lpage>407</lpage>.</citation></ref>
<ref id="bibr57-0961203311430513"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawrence</surname><given-names>CM</given-names></name><name><surname>Marshall</surname><given-names>TL</given-names></name><name><surname>Byrne</surname><given-names>JP</given-names></name></person-group>. <article-title>Lupus erythematosus associated with erythema multiforme-like lesions in identical twins</article-title>. <source>Br J Dermatol</source> <year>1982</year>; <volume>107</volume>: <fpage>349</fpage>–<lpage>356</lpage>.</citation></ref>
<ref id="bibr58-0961203311430513"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heyl</surname><given-names>T</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name></person-group>. <article-title>Lupus erythematosus with erythema multiforme (Rowell's syndrome). A case report</article-title>. <source>S Afr Med J</source> <year>1984</year>; <volume>65</volume>: <fpage>568</fpage>–<lpage>569</lpage>.</citation></ref>
<ref id="bibr59-0961203311430513"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crickx</surname><given-names>B</given-names></name><name><surname>Crickx</surname><given-names>L</given-names></name><name><surname>Vissuzaine</surname><given-names>C</given-names></name><name><surname>Grossin</surname><given-names>M</given-names></name><name><surname>Belaïch</surname><given-names>S</given-names></name></person-group>. <article-title>Chronic lupus erythematosus with erythema multiforme-like lesions (Rowell's syndrome)</article-title>. <source>Ann Dermatol Venereol</source> <year>1985</year>; <volume>112</volume>: <fpage>205</fpage>–<lpage>206</lpage>.</citation></ref>
<ref id="bibr60-0961203311430513"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>JA</given-names></name></person-group>. <article-title>An unusual nitrofurantoin-induced drug reaction</article-title>. <source>Ann Allergy</source> <year>1986</year>; <volume>56</volume>: <fpage>16</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr61-0961203311430513"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis-Jones</surname><given-names>MS</given-names></name><name><surname>Evans</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>CM</given-names></name></person-group>. <article-title>Erythema multiforme occurring in association with lupus erythematosus during therapy with doxycycline</article-title>. <source>Clin Exp Dermatol</source> <year>1988</year>; <volume>13</volume>: <fpage>245</fpage>–<lpage>247</lpage>.</citation></ref>
<ref id="bibr62-0961203311430513"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fiallo</surname><given-names>P</given-names></name><name><surname>Tagliapietra</surname><given-names>AG</given-names></name><name><surname>Santoro</surname><given-names>G</given-names></name><name><surname>Venturino</surname><given-names>E</given-names></name></person-group>. <article-title>Rowell's syndrome</article-title>. <source>Int J Dermatol</source> <year>1995</year>; <volume>34</volume>: <fpage>365</fpage>–<lpage>366</lpage>.</citation></ref>
<ref id="bibr63-0961203311430513"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>EA</given-names></name><name><surname>Purcell</surname><given-names>SM</given-names></name><name><surname>Kantor</surname><given-names>GR</given-names></name><name><surname>Goldman</surname><given-names>HM</given-names></name></person-group>. <article-title>Rowell's syndrome: report of a case</article-title>. <source>J Am Acad Dermatol</source> <year>1996</year>; <volume>35</volume>: <fpage>801</fpage>–<lpage>803</lpage>.</citation></ref>
<ref id="bibr64-0961203311430513"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>SH</given-names></name><name><surname>Giam</surname><given-names>YC</given-names></name><name><surname>Sim</surname><given-names>CS</given-names></name></person-group>. <article-title>Systemic lupus erythematosus with erythema multiforme-like lesions and histiocytic necrotizing lymphadenitis: a case report</article-title>. <source>Ann Acad Med Singapore</source> <year>1996</year>; <volume>25</volume>: <fpage>599</fpage>–<lpage>601</lpage>.</citation></ref>
<ref id="bibr65-0961203311430513"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendonca</surname><given-names>R</given-names></name></person-group>. <article-title>Lupus erythematosus and erythema multiforme-like lesions. Rowell's syndrome</article-title>. <source>Dermatol Online J</source> <year>1997</year>; <volume>3</volume>: <fpage>4</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr66-0961203311430513"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Child</surname><given-names>FJ</given-names></name><name><surname>Kapur</surname><given-names>N</given-names></name><name><surname>Creamer</surname><given-names>D</given-names></name><name><surname>Kobza Black</surname><given-names>A</given-names></name></person-group>. <article-title>Rowell's syndrome</article-title>. <source>Clin Exp Dermatol</source> <year>1999</year>; <volume>24</volume>: <fpage>74</fpage>–<lpage>77</lpage>.</citation></ref>
<ref id="bibr67-0961203311430513"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marzano</surname><given-names>AV</given-names></name><name><surname>Berti</surname><given-names>E</given-names></name><name><surname>Gasparini</surname><given-names>G</given-names></name><name><surname>Caputo</surname><given-names>R</given-names></name></person-group>. <article-title>Lupus erythematosus with antiphospholipid syndrome and erythema multiforme-like lesions</article-title>. <source>Br J Dermatol</source> <year>1999</year>; <volume>141</volume>: <fpage>720</fpage>–<lpage>724</lpage>.</citation></ref>
<ref id="bibr68-0961203311430513"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morand</surname><given-names>JJ</given-names></name><name><surname>Lightburn</surname><given-names>E</given-names></name><name><surname>Guennoe</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Le syndrome de Rowell existe-t-il?</article-title> <source>Les nouvelles Dermatologiques</source> <year>2000</year>; <volume>19</volume>: <fpage>286</fpage>–<lpage>286</lpage>.</citation></ref>
<ref id="bibr69-0961203311430513"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dogra</surname><given-names>A</given-names></name><name><surname>Minocha</surname><given-names>YC</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Capalash</surname><given-names>P</given-names></name></person-group>. <article-title>Rowell's syndrome</article-title>. <source>Indian J Dermatol Venereol Leprol</source> <year>2000</year>; <volume>66</volume>: <fpage>324</fpage>–<lpage>325</lpage>.</citation></ref>
<ref id="bibr70-0961203311430513"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zeitouni</surname><given-names>NC</given-names></name><name><surname>Funaro</surname><given-names>D</given-names></name><name><surname>Cloutier</surname><given-names>RA</given-names></name><name><surname>Gagné</surname><given-names>E</given-names></name><name><surname>Claveau</surname><given-names>J</given-names></name></person-group>. <article-title>Redefining Rowell's syndrome</article-title>. <source>Br J Dermatol</source> <year>2000</year>; <volume>142</volume>: <fpage>343</fpage>–<lpage>346</lpage>.</citation></ref>
<ref id="bibr71-0961203311430513"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramlogan</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>BB</given-names></name></person-group>. <article-title>SLE and erythema multiforme</article-title>. <source>Br J Dermatol</source> <year>2000</year>; <volume>143</volume>: <fpage>130</fpage>–<lpage>133</lpage>.</citation></ref>
<ref id="bibr72-0961203311430513"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandelcorn</surname><given-names>R</given-names></name><name><surname>Shear</surname><given-names>NH</given-names></name></person-group>. <article-title>Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?</article-title> <source>J Am Acad Dermatol</source> <year>2003</year>; <volume>48</volume>: <fpage>525</fpage>–<lpage>529</lpage>.</citation></ref>
<ref id="bibr73-0961203311430513"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pandhi</surname><given-names>D</given-names></name><name><surname>Singal</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>P</given-names></name></person-group>. <article-title>Rowell's syndrome and associated antiphospholipid syndrome</article-title>. <source>Clin Exp Dermatol</source> <year>2004</year>; <volume>39</volume>: <fpage>22</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr74-0961203311430513"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aydogan</surname><given-names>K</given-names></name><name><surname>Karadogan</surname><given-names>S</given-names></name><name><surname>Balaban Adim</surname><given-names>S</given-names></name><name><surname>Tunali</surname><given-names>S</given-names></name></person-group>. <article-title>Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2005</year>; <volume>19</volume>: <fpage>621</fpage>–<lpage>627</lpage>.</citation></ref>
<ref id="bibr75-0961203311430513"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khandpur</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>MK</given-names></name></person-group>. <article-title>Rowell's syndrome revisited: report of two cases from India</article-title>. <source>Int J Dermatol</source> <year>2005</year>; <volume>44</volume>: <fpage>545</fpage>–<lpage>549</lpage>.</citation></ref>
<ref id="bibr76-0961203311430513"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taalauche</surname><given-names>S</given-names></name><name><surname>Derbel</surname><given-names>F</given-names></name><name><surname>Ksontini</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Eythema polymorphe a l’hydrochloroquine cher une patiente atteinte de lupus erythemateux systemique</article-title>. <source>Derm Clin</source> <year>2006</year>; <volume>26</volume>: <fpage>96</fpage>–<lpage>99</lpage>.</citation></ref>
<ref id="bibr77-0961203311430513"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marini</surname><given-names>A</given-names></name><name><surname>Draeger</surname><given-names>H</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Rowell syndrome with palmoplantar involvement and suspected epitope spreading</article-title>. <source>Acta Derm Venereol</source> <year>2006</year>; <volume>87</volume>: <fpage>278</fpage>–<lpage>280</lpage>.</citation></ref>
<ref id="bibr78-0961203311430513"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rathisharmila</surname><given-names>R</given-names></name><name><surname>Niranjan</surname><given-names>B</given-names></name><name><surname>Revathy</surname><given-names>N</given-names></name></person-group>. <article-title>Rowell’s syndrome in a child: a case report</article-title>. <source>Biomedicine</source> <year>2007</year>; <volume>22</volume>: <fpage>77</fpage>–<lpage>78</lpage>.</citation></ref>
<ref id="bibr79-0961203311430513"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>F</given-names></name><name><surname>Senturk</surname><given-names>N</given-names></name><name><surname>Pancar</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus with an erythema multiforme-like lesions</article-title>. <source>Indian J Dermatol</source> <year>2007</year>; <volume>52</volume>: <fpage>56</fpage>–<lpage>58</lpage>.</citation></ref>
<ref id="bibr80-0961203311430513"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meller</surname><given-names>S</given-names></name><name><surname>Hengge</surname><given-names>U</given-names></name><name><surname>Marini</surname><given-names>A</given-names></name><name><surname>Ruzicka</surname><given-names>T</given-names></name><name><surname>Homey</surname><given-names>B</given-names></name></person-group>. <article-title>Rowell-syndrome</article-title>. <source>Hautartzt</source> <year>2007</year>; <volume>58</volume>: <fpage>288</fpage>–<lpage>290</lpage>.</citation></ref>
<ref id="bibr81-0961203311430513"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shadid</surname><given-names>NH</given-names></name><name><surname>Thissen</surname><given-names>CA</given-names></name><name><surname>Van Marion</surname><given-names>AM</given-names></name><name><surname>Poblete-Gutiérrez</surname><given-names>P</given-names></name><name><surname>Frank</surname><given-names>J</given-names></name></person-group>. <article-title>Lupus erythematosus associated with erythema multiforme: Rowell's syndrome</article-title>. <source>Int J Dermatol</source> <year>2007</year>; <volume>46</volume>: <fpage>30</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr82-0961203311430513"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imed</surname><given-names>BG</given-names></name><name><surname>Asma</surname><given-names>SD</given-names></name><name><surname>Mohamed</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Lupus erythemateux systemique associe a des lesions a type l’erytheme polymorphe: syndrome de Rowell ?</article-title> <source>La Tunisie Med</source> <year>2008</year>; <volume>86</volume>: <fpage>406</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr83-0961203311430513"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kacalak-Rzepka</surname><given-names>A</given-names></name><name><surname>Kiedrowicz</surname><given-names>M</given-names></name><name><surname>Bielecka-Grzela</surname><given-names>S</given-names></name><name><surname>Ratajczak-Stefanska</surname><given-names>V</given-names></name><name><surname>Maleszka</surname><given-names>R</given-names></name><name><surname>Mikulska</surname><given-names>D</given-names></name></person-group>. <article-title>Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data</article-title>. <source>Clin Exp Dermatol</source> <year>2008</year>; <volume>34</volume>: <fpage>702</fpage>–<lpage>704</lpage>.</citation></ref>
<ref id="bibr84-0961203311430513"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>AF</given-names></name><name><surname>Mota</surname><given-names>A</given-names></name><name><surname>Tereira</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Rowell’s syndrome: case report and review of literature</article-title>. <source>Dermatol Online J</source> <year>2008</year>; <volume>14</volume>: <fpage>15</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr85-0961203311430513"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modi</surname><given-names>GM</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Mazloom</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Lupus erythematosus masquerading as erythema multiforme: does Rowell’s syndrome really exist?</article-title> <source>Dermatol Online J</source> <year>2009</year>; <volume>15</volume>: <fpage>5</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr86-0961203311430513"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Batra</surname><given-names>P</given-names></name><name><surname>Furer</surname><given-names>V</given-names></name><name><surname>Cheung</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Franks</surname><given-names>A</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Rowell syndrome (systemic lupus erythematosus + erythema multiforme)</article-title>. <source>Dermatol Online J</source> <year>2009</year>; <volume>15</volume>: <fpage>1</fpage>–<lpage>4</lpage>.</citation></ref>
<ref id="bibr87-0961203311430513"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>A</given-names></name><name><surname>Wiss</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Rowell’s syndrome in a pediatric patient</article-title>. <source>J Am Acad Dermatol</source> <year>2009</year>; <volume>60</volume>: <fpage>142</fpage>–<lpage>143</lpage>.</citation></ref>
<ref id="bibr88-0961203311430513"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>V</given-names></name><name><surname>Phillips</surname><given-names>C</given-names></name><name><surname>Schosser</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Rowell syndrome: two cases of lupus erythematosus associated with erythema multiforme</article-title>. <source>J Am Acad Dermatol</source> <year>2010</year>; <volume>64</volume>: <fpage>79</fpage>–<lpage>79</lpage>.</citation></ref>
<ref id="bibr89-0961203311430513"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herrero</surname><given-names>C</given-names></name><name><surname>Bielsa</surname><given-names>I</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases</article-title>. <source>J Am Acad Dermatol</source> <year>1988</year>; <volume>19</volume>: <fpage>1057</fpage>–<lpage>1062</lpage>.</citation></ref>
<ref id="bibr90-0961203311430513"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sontheimer</surname><given-names>RD</given-names></name><name><surname>McCauliffe</surname><given-names>DP</given-names></name><name><surname>Zappi</surname><given-names>E</given-names></name><name><surname>Targoff</surname><given-names>I</given-names></name></person-group>. <article-title>Antinuclear antibodies: clinical correlations and biologic significance</article-title>. <source>Adv Dermatol</source> <year>1992</year>; <volume>7</volume>: <fpage>3</fpage>–<lpage>52</lpage>.</citation></ref>
<ref id="bibr91-0961203311430513"><label>91</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rowell</surname><given-names>NR</given-names></name><name><surname>Goodfield</surname><given-names>MJD</given-names></name></person-group>. <article-title>The connective tissue disease</article-title>. In: <person-group person-group-type="editor"><name><surname>Champion</surname><given-names>RH</given-names></name><name><surname>Burton</surname><given-names>JL</given-names></name><name><surname>Ebling</surname><given-names>FJG</given-names></name></person-group> (eds). <source>Rook’s textbook of dermatology</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Blackwell Science Ltd</publisher-name>, <year>1993</year>; <fpage>2163</fpage>–<lpage>2294</lpage>.</citation></ref>
<ref id="bibr92-0961203311430513"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Provost</surname><given-names>TT</given-names></name><name><surname>Watson</surname><given-names>R</given-names></name><name><surname>Simmons-O'Brien</surname><given-names>E</given-names></name></person-group>. <article-title>Significance of the anti-Ro (SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease</article-title>. <source>J Am Acad Dermatol</source> <year>1996</year>; <volume>35</volume>: <fpage>147</fpage>–<lpage>169</lpage>.</citation></ref>
<ref id="bibr93-0961203311430513"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>A</given-names></name><name><surname>Sticherling</surname><given-names>M</given-names></name><name><surname>Bonsmann</surname><given-names>G</given-names></name></person-group>. <article-title>Clinical manifestations of cutaneous lupus erythematosus</article-title>. <source>J Dtsch Dermatol Ges</source> <year>2007</year>; <volume>5</volume>: <fpage>1124</fpage>–<lpage>1137</lpage>.</citation></ref>
</ref-list>
</back>
</article>